---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-015045"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:25:02.652261+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics receives FDA clearance to proceed with Phase 2a trial of HT-001 for EGFR inhibitor skin toxicities

## Summary
- FDA completed safety review and permitted IND for HT-001 to treat rash and skin disorders from EGFR inhibitor therapy.
- Phase 2a trial (CLEER) is a randomized, placebo-controlled, parallel dose-ranging study.
- European patent application filed for compositions and methods treating lung inflammation.

## SEC filing metadata
- accession: 0001213900-23-015045
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390023015045/0001213900-23-015045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390023015045/ea174379-8k_hoththera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-015045
- JSON: https://secwatch.observer/filing/0001213900-23-015045.json
- Plain text: https://secwatch.observer/filing/0001213900-23-015045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.